Resultado de búsqueda
25 de abr. de 2024 · As of March 31, 2024, Gilead had $4.7 billion of cash, cash equivalents and marketable debt securities, compared to $8.4 billion as of December 31, 2023. During the first quarter 2024, Gilead generated $2.2 billion in operating cash flow.
25 de abr. de 2024 · FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
26 de abr. de 2024 · La compañía estadounidense Gilead Sciences, centrada en el desarrollo de medicamentos en áreas con necesidades médicas no cubiertas en los campos de la virología, la oncología y la inflamación, ha informado este viernes de los resultados del primer trimestre de 2024, que reflejan un progreso significativo de la empresa.
26 de abr. de 2024 · By Nick Paul Taylor Apr 26, 2024 10:04am. Gilead Sciences solid tumor R&D monoclonal antibody. A $4.9 billion hole has appeared in Gilead Sciences' pipeline. After years of setbacks, the Big...
- Nick Paul Taylor
25 de abr. de 2024 · In this article: GILD. Total Revenue: Reached $6.7 billion in Q1 2024, a 5% increase year-over-year, exceeding estimates of $6.338 billion. Net Loss: Reported a significant net loss due to a $3.9...
30 de abr. de 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 14 at 11:20am Pacific Time. RBCCM Global Healthcare Conference on Wednesday, May 15 at 10:30am Eastern Time.
25 de abr. de 2024 · FOSTER CITY, Calif. — FOSTER CITY, Calif. — Gilead Sciences Inc. (GILD) on Thursday reported a loss of $4.17 billion in its first quarter.
